Biography Thomas Miller, PhD is a biomedical researcher and social entrepreneur. He co-founded Paradigm Shift Therapeutics to discover and develop innovative immunotherapies for cancer treatment. Through this venture Tom and his colleagues are pioneering novel public private partnership models to access cutting edge technologies and more equitably share risk with larger stakeholders resulting in more affordable and accessible therapies for patients. Their immune checkpoint inhibitor program is an awardee of National Institutes of Health funding to support a multicenter collaboration between the National Cancer Institute (US), Institut Paoli-Calmettes (FR), and Paradigm Shift Therapeutics.
Tom holds a PhD in chemistry from UCLA and was awarded a cancer research training fellowship to study tumor-immunobiology at the National Cancer Institute where he was the recipient of the NCI Director’s Innovation and Technology Transfer awards.
Tom has authored over 22 scientific papers at the interface of chemistry, biology, and drug discovery. He is currently a Principal Investigator in the Drug Discovery Unit at the Institut Paoli-Calmettes in Marseille France.
Tom is passionate about mentoring young scientists, using chemistry to interpret biology, and translating discoveries to better outcomes for patients.